| Literature DB >> 25254051 |
Tomohito Kakegawa1, Saeko Takase1, Eri Masubuchi1, Ken Yasukawa2.
Abstract
Diarylheptanoids (AO-0001, AO-0002, and AO-0003) isolated from Alpinia officinarum inhibit proinflammatory mediators and exhibit cytotoxic and antiviral activity. However, the precise mechanisms of action of these diarylheptanoids are unknown as are their effects on expression of specific genes. Here, we used a translatome analysis to investigate the mechanisms and modes of action of these three diarylheptanoids. Polysome-associated messenger RNAs (mRNAs) were prepared from diarylheptanoids-treated and control cells from a human B lymphoblastoid cell line; these mRNA samples were then used for microarray analysis. Microarray Data Analysis Tool version 3.2 was used to analyze the microarray data analysis; this software uses pathway information of the WikiPathways for gene ontology analysis. Each of the diarylheptanoids caused upregulation or downregulation of the same 37 and 286 genes, respectively. Among the 37 upregulated genes, 16 were related to mRNA processing based on the WikiPathways analysis. Our findings provided new insights into the mode of action of diarylheptanoids from A. officinarum.Entities:
Year: 2014 PMID: 25254051 PMCID: PMC4164264 DOI: 10.1155/2014/204797
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The chemical structures of AO-0001, AO-0002, and AO-0003.
Figure 2Polysome sedimentation profiles of fractions isolated from control BJAB cells and BJAB cells treated with AO-0001, AO-0002, or AO-0003. The cytosol fraction was layered onto a 0.5 M–1.5 M linear sucrose gradient (prepared by Gradient Master 107, Biocomp) in LSB (20 mM Tris-HCl pH 7.0, 10 mM NaCl, 3 mM MgCl2); the gradient tube was centrifuged at 47,000 rpm in a Hitachi SW55Ti rotor for 70 minutes. A Piston Gradient Fractionator (Biocomp) equipped with an absorbance monitor (254 nm) was used to separate each gradient into nine fractions (0.5 mL/fraction). The absorbance of each 9th fraction (0.5 mL) could not be measured because, in each case, the 9th fraction was retained at the bottom of the ultracentrifuge tube. Positions of ribosomal 40S and 60S subunits and 80S monosomes are indicated by arrows.
Number of transcripts exhibiting altered polysomal loading in BJAB cells following treated with AO-0001, AO-0002, or AO-0003.
| AO-0001 | AO-0002 | AO-0003 | Common Gene | ||||
|---|---|---|---|---|---|---|---|
| Probe∗ | Gene | Probe∗ | Gene | Probe∗ | Gene | ||
| Downregulated (ratio ≦ 0.5) | 965 | 634 | 950 | 663 | 900 | 585 | 37 |
| Upregulated (ratio ≧ 2) | 1308 | 994 | 1960 | 1349 | 1574 | 1222 | 286 |
| Total altered |
|
|
|
|
|
|
|
*Total of 54359 probes were used.
Figure 3Scatter plot of normalized intensities versus control intensities (a) and of normalized intensities of genes affected by each diarylheptanoid (b). (a) Net intensity for each spot: the net intensity was calculated by subtracting surrounding background intensity, which was derived from row intensity, from the intensity of the respective spot. Normalization was performed by adjusting the median of all the read microarray data relative to a fixed value. After the net intensity of each probe was normalized, a sample versus control ratio was calculated. For those probes with 2-fold upregulation (Ratio ≥ 2) or downregulation (Ratio ≤ 0.5) in treated cells and that exhibited a normalized net intensity of more than 40, the net intensity values were plotted. (b) Normalized net intensity values of genes that were regulated by each diarylheptanoid were potted versus control normalized net intensity values.
Number of WikiPathways transcripts that exhibited altered polysomal loading following AO-0001, AO-0002, or AO-0003.
| WikiPathways |
Total gene | AO-0001 | AO-0002 | AO-0003 | |||
|---|---|---|---|---|---|---|---|
| Pathway name |
| Altered gene number |
| Altered gene number |
| Altered gene number | |
| Alanine and aspartate metabolism WP106 41117 | 12 | 2.73 | 4 | 3.33 | 5 | ||
| Apoptosis WP254 41184 | 79 | −2.18 | 2 | −2.45 | 2 | ||
| Calcium regulation in the cardiac cell WP536 41204 | 145 | −2.19 | 8 | ||||
| Cell cycle WP179 45137 | 72 | 2.93 | 16 | ||||
| Diurnally regulated genes with circadian orthologs WP410 41104 | 42 | 2.52 | 9 | ||||
| DNA replication WP466 41036∗1 | 38 | 3.95 | 11 | 13 | |||
| Glycolysis and gluconeogenesis WP534 41077 | 45 | 3.29 | 11 | 14 | |||
| GPCRs, class A rhodopsin-like WP455 41121∗2 | 227 | −3.40 | 7 | −2.67 | 13 | −3.05 | 11 |
| MAPK signaling pathway WP382 41048∗3 | 153 | −2.10 | 9 | ||||
| mRNA processing WP411 45374∗4 | 110 | 7.40 | 34 | 5.54 | 31 | 9.80 | 45 |
| Proteasome degradation WP183 45274 | 52 | 3.09 | 13 | ||||
| Translation factors WP107 41026 | 42 | 3.02 | 11 | 3.05 | 11 | ||
WikiPathways transcripts with a P value < 0.5 are listed.
∗1DNA: deoxyribonucleic acids
∗2GPCRs: G protein-coupled receptors
∗3MAPK: mitogen-activated protein kinases
∗4The following 16 transcripts were each upregulated after treatment with each diarylheptanoid (AO-0001, AO-0002, or AO-0003). CSTF1: cleavage stimulation factor, 3′ pre-RNA, subunit 1, 50 kDa; CSTF3: cleavage stimulation factor, 3′ pre-RNA, subunit 3, 77 kDa; DDX1: DEAD (Asp-Glu-Ala-Asp) box helicase 1; FUS: fused in sarcoma; HNRNPAB: heterogeneous nuclear ribonucleoprotein A/B; HNRNPC: heterogeneous nuclear ribonucleoprotein C (C1/C2); HNRNPK: heterogeneous nuclear ribonucleoprotein K; NONO: non-POU domain containing, octamer-binding; PTBP1: polypyrimidine tract binding protein 1; PRPF40A: PRP40 pre-mRNA processing factor 40 homolog A (S. cerevisiae); PRPF6: PRP6 pre-mRNA processing factor 6 homolog (S. cerevisiae); SRSF7: serine/arginine-rich splicing factor 7; SNRNP70: small nuclear ribonucleoprotein 70 kDa (U1); SF3A3: splicing factor 3a, subunit 3, 60 kDa; SF3B2: splicing factor 3b, subunit 2, 145 kDa; U2AF2: U2 small nuclear RNA auxiliary factor 2.
Features of 5′ UTRs in transcripts for which AO-0001, AO-0002, and AO-0003 each caused altered polysomal loading.
| Upstream open reading frame | In-frame stop codon | Other features | ||||
|---|---|---|---|---|---|---|
| Number of transcripts | % of total | Number of transcripts | % of total | Number of transcripts | % of total | |
| Downregulated (Ratio ≦ 0.5) | 5 | 14% | 16 | 43% | 16 | 43% |
| Upregulated (Ratio ≧ 2) | 41 | 14% | 156 | 53% | 95 | 33% |